Advocacy intelligence hub — real-time data for patient organizations
National Cancer Institute (NCI) — PHASE2
Centre Hospitalier Universitaire de Nice
Data from FDA regulatory filings and ClinicalTrials.gov. Updated periodically.
FINANCIAL LANDSCAPE SUMMARY
Total programs
Open now
Patient Assistance Programs1
VYXEOS ; Vyxeos ; Vyxeos
Celator Pharmaceuticals, Inc. (a Jazz Pharmaceuticals Company)
VYXEOS
(Cytarabine:daunorubicin liposome injection; daunorubicin and cytarabine (liposome); daunorubicin and cytarabine liposome for injection)Orphan drugstandardCelator Pharmaceuticals, Inc. (a Jazz Pharmaceuticals Company)
Rydapt
(RYDAPT)Orphan drugstandardNovartis Pharmaceuticals Corporation
Kinase Inhibitor [EPC]
12.1 Mechanism of Action Midostaurin is a small molecule that inhibits multiple receptor tyrosine kinases. In vitro biochemical or cellular assays hav...
Browse all Acute myeloid leukaemia with myelodysplasia-related features news →
Brenda Sandmaier
Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium
📍 SEATTLE, WA
B. Smith, M.S.W., L.C.S.W
Johns Hopkins University
📍 OKLAHOMA CITY, OK
Judith Karp, M.D
Johns Hopkins University/Sidney Kimmel Cancer Center
📍 BALTIMORE, MD
Courtney DiNardo, MD
M.D. Anderson Cancer Center
📍 HOUSTON, TX
Bart Scott
Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium
📍 SEATTLE, WA
Roland Walter, MD PhD
Fred Hutch/University of Washington Cancer Consortium
📍 SEATTLE, WA
View all Acute myeloid leukaemia with myelodysplasia-related features specialists →